Evidence map›Paper›PMID 40207810›Full record

ReviewCurrent rheumatology reviews2026

Virtual Screening Approaches Towards the Discovery of Toll-like Receptor 7 (TLR7) Antagonists for the Management of Rheumatoid Arthritis During COVID Infection.

Thangavelu Prabha, Saravanan Thangavelu, Dakshinesh Parameswaran, Muthu Kumaradoss Kathiravan, Hemalatha Selvaraj, Motamarri Venkata Naga Lalitha Chaitanya, Sridhar Sri Bhuvaneswari, Jubie Selvaraj

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thangavelu PrabhaDepartment of Pharmaceutical Chemistry, Nandha College of Pharmacy, Affiliated with The Tamil Nadu Dr. MGR Medical University, Chennai, Erode, 638052, Tamil Nadu, India.
Saravanan ThangaveluDepartment of Anaesthesiology, Government Medical College and Hospital, Pudukkottai, 622004, Tamil Nadu, India.
Dakshinesh ParameswaranDepartment of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-603203, Chengalpattu, Tamil Nadu, India.
Muthu Kumaradoss KathiravanDepartment of Pharmaceutical Chemistry, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu, 603203, India.
Hemalatha SelvarajDepartment of Pharmacy Practice, Faculty of Pharmacy, Karpagam Academy of Higher Education, Coimbatore, 641021, Tamil Nadu, India.
Motamarri Venkata Naga Lalitha ChaitanyaSchool of Pharmacy, Lovely Professional University, Phagwara, Punjab, India.
Sridhar Sri BhuvaneswariDepartment of Pharmaceutical Chemistry, Nandha College of Pharmacy, Affiliated with The Tamil Nadu Dr. MGR Medical University, Chennai, Erode, 638052, Tamil Nadu, India.
Jubie SelvarajDepartment of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Tamil Nadu, India.ORCID 0000-0002-4633-6621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatoid arthritis(RA) patients prompt to have high level of TLR7, when coronavirus (CoV-2) infect to these patients, further the level of TLR7 cloud be upregulated and leads to severe condition of RA. Since, some TLR7 antagonists targeting the TLR7 protein are in the clinical trials, but yet to reach the market, and many lead to serious toxicities.

objectiveSo, we have framed a hypothesis to discover the TLR7 antagonist that may inhibit to the upregulation of TLR 7 in RA patients during the CoV-2 infection via virtual screening methodology.

methodsHere we have focused to discover some novel TLR7 inhibitors from the ZINC database, which may effectively inhibit TLR7. Series of virtual screening analysis lead to the discovery of three active hits. RESULTS AND DISCUSSION: Among these three molecules, ZINC95412580 had a highest binding energy of -15.4273 kcal/mol against the TLR7 protein (PDB Id: 6LW1) that also showed the maximum interactions within the binding pocket. c Conclusion: Thus, the compounds discovered through the use of various software can possibly be used for the management of rheumatoid arthritis during and after COVID infection. Hence, we can conclude that these molecules might be served as the inhibitors of TLR7 upregulation.

Indexed as

Arthritis, RheumatoidToll-Like Receptor 7COVID-19Drug DiscoveryHumansPandemicsSARS-CoV-2TLR7 protein, humanToll-Like Receptor 7clinical trialsCOVID-19pharmacophore mappingRheumatoid arthritistoll-like receptor 7 antagonistvirtual screening

Identifiers

PMID40207810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.